Gregg Sando

Founder and CEO

After a successful, 22-year-long career in investment banking based in London and New York, Gregg completed his MSc degree in immunology at Imperial College School of Medicine, London.

Recognizing the significant progress taking place in the field of cellular immunotherapy, Gregg formed Cell Medica in collaboration with a small group of leading clinicians and immunologists who were pioneering this new type of medical treatment.

Gregg holds an MSc in immunology from Imperial College School of Medicine in London, as well as an MBA from the University of Chicago and a BA in biochemistry from Harvard University.

Karen Hodgkin

COO, Chief Operating Officer

Karen has over 30 years of experience in planning and running clinical trials, which has been invaluable in the creation of Cell Medica’s highly-efficient clinical operations and regulatory function. After working as SVP, Clinical Operations, Karen has moved to become Cell Medica’s COO in September 2016.

In the past, Karen has worked for Boehringer Ingelheim (UK), ICN Pharmaceuticals (UK) and British Biotech (UK/US) and as a clinical operations consultant in the US. Her experience spans a range of therapeutic applications and has been acquired whilst running single and multicenter studies globally.

Karen has a Diploma in Clinical Science from the University of Wales Institute of Science & Technology, an MSc in Bio pharmacy from King’s College London and a BSc in pharmacology from Leeds University in the UK.

Dr Luis Borges

CSO, Chief Scientific Officer

Luis has over 21 years of experience working in the discovery and development of novel therapies for cancer treatment. After earning his doctorate degree in Pathology at the University of Washington in Seattle, Luis began his drug development career at Immunex, where he gained significant experience in immunology and cancer immunotherapy. After the acquisition of Immunex by Amgen, Luis transitioned to the Hematology and Oncology Department where he led numerous drug development teams and provided research support for several blockbuster drugs.  In 2014, Luis joined Five Prime Therapeutics, to help transition the company into cancer immunotherapy. He served as Senior Vice President of Research and was instrumental in rebuilding the research pipeline. He re-shaped and grew the research organization and in the space of three years, his group transitioned three new drug candidates into IND-enabling studies. Luis’s extensive scientific and drug expertise includes significant experiences with various antibodies technologies and development of a wide array of engineered biologics targeting not just tumor cells, but also various immune cell types including T cells, NK cells, and dendritic cells.  Dr Borges work has been published in a number of peer-reviewed journals.

Kevin Boyle


Kevin has over 20 years of diversified finance experience helping companies define and achieve strategic financial objectives.  He has broad international experience with both public and private companies and has raised over $2.0 billion in capital over his career.

Before joining Cell Medica, Kevin served as Chief Financial Officer of FloWorks International and had held previous senior finance roles at Sigma Cubed, RecoverCare and SPT.  Kevin graduated from Carnegie Mellon University with a B.S. in Industrial Management, and earned his J.D. from the University of Pennsylvania. He is active in the Houston community, serving as Treasurer of The Center for Hearing and Speech and on the Advisory Board of the Hermann Park Conservancy.

Lynn Lester

SVP, Human Resources

When joining Cell Medica, Lynn brought over a decade of senior HR experience at leading UK biotechnology companies with her.

Prior to joining Cell Medica, Lynn held the position of Vice President of Human Resources at ApaTech, a UK-based orthobiologics firm. Before this, Lynn held the position of Senior Vice President of Human Resources and Business Operations at Cambridge Antibody Technology, one of the UK’s leading biotechnology companies. While at Cambridge Antibody Technology, Lynn was responsible for doubling the headcount and facilities following a takeover by AstraZeneca.

Lynn has an MBA and Diploma in Management from the Open Business School and a Certificate in Education from the University of Leeds in the UK.

Dr Ross Durland

SVP, Development

Ross has over 25 years of experience in the development of innovative therapeutic products and technologies and is responsible for spearheading the product development process at Cell Medica.

His experience includes eight years developing human gene therapies at Valentis, where he became Senior Director Preclinical Development. In this role, he led multisite, multidisciplinary product development teams, advancing two new gene therapy products from animal proof-of-concept to human clinical testing, and supported development of five additional clinical stage products through Phase IIb testing. He was also responsible for Valentis’ manufacturing and quality control functions in manufacturing products for preclinical and clinical testing. Ross also served as Vice President of Product Development at Altea Therapeutics, where he led preclinical and clinical development of two novel human transdermal therapeutic products.

Ross has a PhD in molecular biology from the University of California San Diego and a BS in biology from Texas A&M University.

Dr Kurt Gunter

CMO, Chief Medical Officer

Kurt has devoted his career to the development of cell and gene therapies and brings significant commercial experience to Cell Medica from his previous positions at Hospira, ViaCell, and Transkaryotic Therapies. At Cell Medica, Kurt is in charge of Clinical Operations, Medical and Scientific Affairs and Regulatory Affairs.

As past President of the International Society for Cellular Therapy (ISCT), Kurt played a worldwide leadership role in promoting understanding of the clinical, regulatory, manufacturing, and marketing requirements for the successful development of cell and gene therapies. Prior to his biotech career, he worked at the United States Food and Drug Administration as a Medical Officer in the Center for Biologics and was appointed Acting Deputy Director of the Division of Cell and Gene Therapy within the Center for Biologics Evaluation and Research.

Kurt earned his MD from the University of Kansas and also has a BS in biological sciences, with distinction, from Stanford University. His postdoctoral training included Johns Hopkins and the US National Institutes of Health.

Dr Stefanos Theoharis

SVP, Corporate Development and Partnering

Stefanos joined Cell Medica to lead our partnering activities, bringing a combination of academic, business development, project management and finance skills.

Following his PhD, Stefanos worked as a post-doctoral researcher at Imperial College, whilst also working for six years in parallel as a paid consultant to the London Technology Network, a government-funded organization bridging the gap between industry and academia. Subsequently, Stefanos joined Lazard, the investment bank, as a member of the life science M&A team and then Roche Partnering, as Director of Emerging Technologies, where he participated in multiple licensing deals, with a focus on novel innovative technologies. He then joined Antisense Pharma as Head of BD. Prior to joining Cell Medica, Stefanos was CBO for apceth in Munich, where he was responsible for business development on the company’s first-in-man engineered cell therapy platform and its GMP manufacturing business, as well as project management, and communications.

Stefanos holds a PhD in gene therapy and immunology and a MSc in Molecular Medicine both from Imperial College.

Dr Annalisa Jenkins

Chair of the Board of Directors

Annalisa Jenkins, MBBS, FRCP, joined the Board of Directors as Chairperson in December 2017. Prior to joining Cell Medica, Dr. Jenkins served as President and CEO of Dimension Therapeutics and held multiple leadership positions, including Executive Vice President, Head of Global Research and Development for Merck Serono, where she led global medical affairs and quality and was a member the Pharmaceutical Executive Committee.  Prior to this, Dr. Jenkins had a successful 14-year career at Bristol-Myers Squibb (BMS), attaining the role of Senior Vice President and Head of Global Medical Affairs. Dr. Jenkins graduated with a degree in medicine from St. Bartholomew’s Hospital, University of London and subsequently trained in cardiovascular medicine in the U.K. National Health Service. Dr. Jenkins is a board member of several growing companies and a member of the Science Board to the U.S. Food & Drug Administration (FDA).  She also serves on the board of the Center for Talent Innovation in the U.K.

Dr Thomas Hecht

Non-Executive Director

Thomas has been on the Cell Medica Board since 2012 and he was Chairman until December 2017. He was previously Vice President Marketing at Amgen Europe, Lucerne, Switzerland. Following his academic career, he held various positions of increasing responsibility in clinical development, medical affairs and marketing at Amgen between 1989 and 2002. Prior to joining the biopharmaceutical industry, he served as Co-Head of the Program for Bone Marrow Transplantation, University of Freiburg, Germany.
Today, he provides services to the pharmaceutical industry in clinical development/ marketing and licensing strategies.
He also serves as Chairman of Affimed NV, Vaximm AG and Aelix Therapeutics SA. In 2009, with the acquisition by Alcon, he stepped down as Chairman of ESBATech AG; and in 2015, with the acquisition by Baxter International Inc., from his post as Chairman of the Supervisory Council of SuppreMol GmbH.
Thomas earned his MD at the University of Freiburg.

Dr Nigel Burns

Non-Executive Director

Nigel has extensive experience in product and company management and has held a series of leadership roles, one of which was Senior Vice President at Cambridge Antibody Technology. Nigel has also held a number of Board level positions in companies such as Glythera and currently at Cell Medica. Additionally, he was formerly non-executive Director of Navion, Director and Founder of Nascient and, most recently, CEO and Founder of SweetSpot Therapeutics Ltd. Furthermore, he was an entrepreneur-in-residence for Imperial Innovations and has served on multiple national and international scientific and industry advisory boards and committees.

Nigel has a PhD in biophysics from King’s College, London and a BSc in biochemistry from Imperial College London.

Dr Allan Marchington

Non-Executive Director

Allan Marchington is an experienced investor with a strong track record of success. In 2006 Allan and his Partners founded Apposite Capital, an international healthcare investment company based in London. While at Apposite, Allan has served on the Board of a number of companies including Calchan Ltd., Birdrock Bio Inc., Ambrx Inc., Ambit Biosciences Inc., Convergence Pharmaceuticals Ltd, and Sotera Wireless. Prior to establishing Apposite, Allan worked in a number of senior roles, including Entrepreneur in Residence, Abingworth Management and Senior Vice President, Millennium Pharmaceuticals Inc. based in Cambridge Mass. Prior to Millennium, Allan was principal founder and CEO of Cambridge Combinatorial, a combinatorial chemistry company which was successfully sold to Millennium in 2000. Allan has a PhD in Chemistry from the University of Liverpool and after leaving University, worked for seven years in a range of therapeutic areas at Pfizer.

Sam Williams

Non-Executive Director

Sam is Managing Partner, Life Sciences, at IP Group plc. He has 20 years’ experience in the biotech sector, both as a top-ranked equity analyst in the City of London and, subsequently, as a chief executive. He currently serves as Executive Chairman of Istesso Ltd, Chairman of Glythera Ltd and a non-executive director of Diurnal Group plc, C4X Discovery Holdings plc and Microbiotica Ltd. Sam has a PhD in molecular biology from Cambridge and a degree in biology from Oxford.

Gregg Sando

Founder and CEO

After a successful, 22-year-long career in investment banking based in London and New York, Gregg completed his MSc degree in immunology at Imperial College School of Medicine, London.

Recognizing the significant progress taking place in the field of cellular immunotherapy, Gregg formed Cell Medica in collaboration with a small group of leading clinicians and immunologists who were pioneering this new type of medical treatment.

Gregg holds an MSc in immunology from Imperial College School of Medicine in London, as well as an MBA from the University of Chicago and a BA in biochemistry from Harvard University.

Prof M. Lowdell

Prof. Lowdell is a Professor of Cell & Tissue Therapy and the Director of Cellular & Biobanking at the Royal Free Hospital, London. He is a member of the Cancer Biology and Translational Research Group, the Institute of Biomedical Engineering, and the University College London Centre for Stem Cells & Regenerative Medicine.

Prof S. Mackinnon

Prof. Mackinnon is a Professor of Hematology at University College London and heads the Bone Marrow and Stem Cell Program at University College Hospital, London.

Prof P. Moss

As professor of Hematology, Head of the Cancer Research UK Centre at the University of Birmingham, Chairman of the Cancer Research UK Clinical and Translational Research Committee, and Deputy Chairman of the Medical Research Council Infection and Immunity Board, Prof. Moss is a leading figure in the field of T-cell immunotherapy.

Prof C. Pusey

Prof. Pusey is the Head of both the Renal Section in the Department of Medicine and the Postgraduate Medicine Program at Imperial College London. He is also a Consultant Physician and the Lead Clinician in the Renal Directorate as well as holding a professorship in Medicine.

Prof S. Riddell

Prof. Riddell is a Professor of Medicine and Assistant Program Head of the Program in Immunology at the Fred Hutchinson Cancer Center. He has extensive knowledge in the fields of T cell immunotherapy and medical oncology.

Prof C. Rooney

Prof. Rooney is a Professor in the Department of Pediatrics, in the sections of Hematology-Oncology and Pathology & Immunology at the Baylor College of Medicine in Texas. T cell immunotherapy is her specialty.

Prof G. Screaton

Prof. Screaton holds the Chair in Medicine at Imperial College London and heads a department of over 900 research and support staff while continuing to perform ground-breaking T cell immunotherapy research.

His expertise in the fields of T cell biology and human immune responses to viruses allows Cell Medica to provide truly innovative therapies to patients.

Prof H. Stauss

Prof. Stauss is Professor of Tumor Immunology in the Division of Infection & Immunity of the Research Department of Immunology of the Faculty of Medical Sciences at University College Hospital, London.